Nucleotech LLC
This article was originally published in Start Up
Executive Summary
Cell therapy start-up Nucleotech LLC is developing an in vitro method for reprogramming mature cells, transdifferentiating them into other kinds of mature cells for autologous therapeutic use against diabetes, cancer, cardiac disease and a host of other indications.
You may also be interested in...
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)
In Vivo's 2017 Deals Of The Year: The Winners Are…
We nominated 15 deals in three categories. You picked the winners.